论文部分内容阅读
所谓新一代CTC检测技术是通过包裹了多肽的纳米磁珠捕获外周血中的循环肿瘤细胞,以实现肿瘤早期发现。因为绝大多数恶性肿瘤出现在人体的上皮组织细胞,从肿瘤组织脱落的上皮细胞进入外周血循环成为循环肿瘤细胞(Circulating Tumor Cell,简称“CTC”),它是肿瘤检测的重要生物标志物。这些细胞的特点是血液中含量极低且微小,运用多肽纳米磁珠技术捕获这些肿瘤细胞,可以实现肿瘤早期发现。肿瘤早期发现,及时采取积极有效的干预,患者的五年生存率能达到90%左右;而晚期肿瘤患者的五年
The so-called next-generation CTC detection technology is to capture circulating tumor cells in the peripheral blood by nano-magnetic beads wrapped in peptides to achieve early detection of tumors. Because most malignant tumors are found in human epithelial cells, epithelial cells shed from the tumor tissue enter the peripheral blood into circulating circulating tumor cells (“CTCs”), which are important biomarkers for tumor detection . These cells are characterized by extremely low and minimal amounts of blood and the use of peptide nanocarrier technology to capture these tumor cells allows for the early detection of tumors. Early detection of tumors, take timely and effective intervention, the patient’s five-year survival rate can reach about 90%; and advanced cancer patients for five years